The Johnson & Johnson vaccine provides a good immunological response

El laboratorio estadounidense Johnson & Johnson reported the New England Journal of Medicine, and the publication of the terms of phase 1 / 2a containing the holiday date Covid-19, available from Janssen Pharmaceutical Companies, proportions a response in less than 71 days in the study participants from 18 to 55 years.

The company also adelantó que the dates on the durability of the immunizations in the major cities of 65 years will be available in fines and plan a follow-up to more than one year ago. Laboratory expectations present the Phase 3 dates, this is my own.

The so-called “Ad26.COV2.S” vaccine is administered as a single dose, which means a great deal of success over the current developments, and could provoke an acceleration in the evacuation campaigns throughout the world.

Following the expectations, the pharmaceutical company estadounidense and its Belgian branch Janssen, should apply for an authorization for the European commercialization of its vacancy next month, dijo el miércoles la commisaria europea Stella Kyriakides, encargada del área salud.

The European Regulatory Agency (EMA) has been examining a “continuous revision” of the December principles, by which the authorization should be expedited. The Commission has approved an advance purchase agreement with Janssen for 200 million of his vacancy, with 200 million more as options.

“The meta line of our vaccine is in sight. We have a very large marching studio in three continents, North America, South America and Africa. We include 40,000 people ”, explained by the company.

As a result, the American group will be hosting the green light in the EU, having authorized the communications regulator of vacancies (the BioNTech-Pfizer and Modern) and a third (AstraZeneca-Oxford) light in the green light in the next week.

A first vacancy in Europe

The European Commission’s petition to demand that a mayoral administration of vacancies be lodged, the notice of Johnson & Johnson let that dose actually increase considerably, at a time when the sanitary authorities recognize that the contagios are under control.

Without embarrassment, we are talking to the Ministries of Health of the United States, the European Commissioner Stella Kyriakides said that “there are no vacancies” that will save lives, without the “vacancy”. There is the importance of following the real injection of all these doses. “It has provided the Member States with information on weekly calls to the ECDC” (European Center for Prevention and Control) on the progress of their evacuation campaign, dijo.

The question of the “parallel” agreements celebrated by certain States, and in particular the criticisms of the negotiations that led Germany, should be questioned. The European Commission has approached the 27 companies that are compromising, validating the EU-level centralized negotiation, and not conducting parallel negotiations with the same companies.

An ambitious prognosticator

The company’s scientific director, Paul Stoffels, said the lab was on the way to launch its single vehicle in March. In an interview, the directive also says that J&J hopes to complete its stated goal of generating millions of doses of its vaccine by the end of this year, while the company has increased production.

Stoffels indicates that it was premature to count the doses of starch available in March, adding that the company receives an emergency authorization from the European Food and Drug Administration (FDA).

For the diary New York Times, this assertion is somewhat ambitious, as only the laboratory is informed that experiments are being carried out during the manufacture which will reduce the amount of doses available initially.

At present, Johnson & Johnson plans to publish the results of its study for its Covid-19 vaccine on weekdays only, but it is probable that no dose can be administered during the northern hemisphere primordial period as long-term compromise of manufacturing failure occurs; revela el New York Times. The pharmaceutical company adelantado has 12 million doses of its vaccine lists for the end of February, raising a total of 100 million doses for June ends.

The periodic date when the company returned within two months of the original production program and did not reach the final dates of April, when it was announced that it had withdrawn more than 60 million doses. following familiar characters with the help.

Other candidates for Argentina

Initiated the evacuation campaign with the first 300 miles of Sputnik V evacuations to the Russian government, otros desarrollos pueden accelerate the rhythm of an immunization that hopes to have a more important dose of dosing.

The official projections surge that the March fines will increase the massive distribution of Oxford’s formula developed by Astrazeneca and produced – and partly – in the province of Buenos Aires. In addition, there are conversations initiated with Chinese suppliers Sinopharm and Sinovac.

The Minister of Health, Guinea’s González García, reveals the existence of conversations with Janssen, owned by Johnson & Johnson, on the basis of which a good news report will be generated, which may generate some expectation in its antiquated plan and actual march.

MORE ABOUT THIS THEME:

Italy extends its restrictive measures against coronavirus pandemic March 5

The strategy of Palaos, the paradise island of the Pacific that follows the eviction of COVID-19